Document Detail

Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing?
MedLine Citation:
PMID:  17039659     Owner:  NLM     Status:  MEDLINE    
Acrodermatitis continua of Hallopeau (ACH) is a rare disease. Little is known about its etiology or relative effectiveness of the various therapeutic approaches. However, in the literature a pattern seems to be developing on successfully treated patients using biologic therapies. Here, we further emphasize the potential breakthrough presented by the novel immune based therapies. This report consists of a case of etanercept responsive ACH along with a brief review of the literature.
Brian Bonish; Rashid M Rashid; James Swan
Related Documents :
17039659 - Etanercept responsive acrodermatitis continua of hallopeau: is a pattern developing?
6217229 - Eccrine hidrocystomas.
15134579 - Positive pleiotropic effects of hmg-coa reductase inhibitor on vitiligo.
23930089 - Making the critical appraisal for summaries of evidence (case) for evidence-based medic...
3141209 - Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia.
12685959 - Galactosemia: a treatable metabolic disorder.
15455629 - Actinomycosis in neck glands.
2657709 - Congenital cystic hygroma of the neck diagnosed prenatally: outcome with normal and abn...
9749889 - Pseudomyxoma peritonei--a heterogenous disease.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of drugs in dermatology : JDD     Volume:  5     ISSN:  1545-9616     ISO Abbreviation:  J Drugs Dermatol     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-16     Completed Date:  2006-11-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160020     Medline TA:  J Drugs Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  903-4     Citation Subset:  IM    
Department of Dermatology, Loyola Medical Center, Maywood, IL 60153, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acrodermatitis / diagnosis,  drug therapy*,  pathology
Administration, Cutaneous
Anti-Inflammatory Agents / administration & dosage,  therapeutic use*
Desoximetasone / administration & dosage,  therapeutic use*
Diagnosis, Differential
Drug Therapy, Combination
Immunoglobulin G / therapeutic use*
Receptors, Tumor Necrosis Factor / therapeutic use*
Recombinant Fusion Proteins / therapeutic use*
Tumor Necrosis Factor-alpha*
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Recombinant Fusion Proteins; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein; 382-67-2/Desoximetasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An intertrigo-like eruption from pegylated liposomal doxorubicin.
Next Document:  Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%.